329924-46-1

Basic information

• Product Name: 5-(o-methoxyphenoxy)-4,6-dihydroxy-2-(N-morpholino)-pyrimidine
• Synonyms: 5-(o-methoxyphenoxy)-4,6-dihydroxy-2-(N-morpholino)-pyrimidine
• CAS NO: 329924-46-1
• Molecular Weight: 0
• Mol File: 329924-46-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 5-(o-methoxyphenoxy)-4,6-dihydroxy-2-(N-morpholino)-pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(o-methoxyphenoxy)-4,6-dihydroxy-2-(N-morpholino)-pyrimidine(329924-46-1)
• EPA Substance Registry System: 5-(o-methoxyphenoxy)-4,6-dihydroxy-2-(N-morpholino)-pyrimidine(329924-46-1)

Safety Data

• Hazardous Substances Data: 329924-46-1(Hazardous Substances Data)

Upstream product

• 20730-58-9 2-(2-Methoxyphenoxy)propanedioic acid diethyl ester 
• 5638-78-8 morpholinoformamidine hydrochloride 
• 1878-85-9 (2-methoxyphenoxy)acetic acid 
• 157415-17-3 Morpholine-4-carboxamidine; hydrobromide 
• 150726-89-9 (2-methoxyphenoxy)-malonic acid dimethyl ester 
• 38768-62-6 methyl (2-methoxyphenoxy) ethanoate 

Downstream Products

• 167403-77-2 4,6-dichloro-5-(2-methoxy-phenoxy)-2-(morpholin-4-yl)pyrimidine 
• 346671-60-1 4-tert.-butyl-N-[6-(4-hydroxy-2-butynyloxy)-5-(2-methoxy-phenoxy)-2-morpholin-4-yl-pyrimidin-4-yl]-benzene sulfonamide 
• 167403-78-3 4-tert.-butyl-N-[6-chloro-5-(2-methoxy-phenoxy)-2-morpholin-4-yl-pyrimidin-4-yl]-benzene sulfonamide 

Relevant articles and documents

The discovery of N -[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy] ethoxy]-4-pyrimidinyl]- N ′-propylsulfamide (macitentan), an orally active, potent dual endothelin receptor antagonist

Starting from the structure of bosentan (1), we embarked on a medicinal chemistry program aiming at the identification of novel potent dual endothelin receptor antagonists with high oral efficacy. This led to the discovery of a novel series of alkyl sulfamide substituted pyrimidines. Among these, compound 17 (macitentan, ACT-064992) emerged as particularly interesting as it is a potent inhibitor of ETA with significant affinity for the ET B receptor and shows excellent pharmacokinetic properties and high in vivo efficacy in hypertensive Dahl salt-sensitive rats. Compound 17 successfully completed a long-term phase III clinical trial for pulmonary arterial hypertension.

Butyne diol derivatives

The present invention relates to novel butyne diol derivatives of the general formula I and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of the general formula I and especially their use as endothelin receptor antagonists.